ALKERMES | ALKS - Ebitda

Prezzo Delle Azioni
37.48
Cambio Giornaliero
-0.88 -2.29%
Mensile
11.00%
Annuale
19.29%
Q2 Previsione
36.35




Ebitda Cambiamento Data
AbbVie USD 5.37B 1.85B 2025-12
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
ALKERMES USD 80.26M 20.05M 2026-03
Amgen USD 5.14B 775M 2025-12
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 12.14B 4.26B 2025-12
Gilead Sciences USD 3.02B 1.01B 2025-12
Heron Therapeutics USD -3.88M 5.63M 2024-09
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
J&J USD 7.19B 2.32B 2025-12
Malin Corporation EUR -1.1M 200K 2024-12
Merck USD 6.3B 2.09B 2025-12
Minerva Neurosciences USD -4.36M 1.71M 2024-09
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Otsuka Holdings JPY 156.66B 56.89B 2026-03
Pfizer USD 5.99B 5.23B 2026-03
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03